Improved product capabilities of preclinical animal imaging systems hold them in good stead despite a shortage of funding, according to a new Frost & Sullivan report that analyzed the characteristics of the U.S. preclinical animal imaging systems market since 2006.
Frost & Sullivan's expert analysts examined the following technologies: preclinical optical imaging systems, preclinical nuclear systems, micro-PET, micro-PET/CT, micro-SPECT, micro-SPECT/CT, tri-modality, preclinical CT systems (micro-CT), preclinical MRI systems and preclinical high-frequency ultrasound systems.
The preclinical animal imaging systems market has bounced back from the consolidation in the pharmaceuticals and biotechnology industries, limited grant funding and shortage in the supply of medical isotopes by enhancing its product capabilities, said the report.
In addition, the markets evolving competitive landscape and the increasing acceptance of imaging as a standard in preclinical animal research are expected to bolster it till 2016.
Moreover, the substantial downsizing and consolidation in the pharmaceuticals and biotechnology industries over the last couple of years have compelled potential customers to tighten their purse strings and substantially reduce preclinical research budgets.
Relatively low-cost, easy-to-use, and easy-to-site preclinical imaging systems capable of providing adequate performance in the vast majority of new and existing preclinical imaging applications are becoming more widely available, noted the report. However, further market penetration may not be easily achievable until the pharmaceuticals and biotechnology industries stabilize and are able to budget the capital necessary to acquire one or more preclinical imaging systems.